Epigenetic therapy has emerged as a novel approach, not necessarily by killing cancer cells, but perhaps by altering the network of chemical changes that affect the DNA/chromatin within cancer cells.
Ronan T. Swords, MD, PhD
Advertisement
Articles by Ronan T. Swords, MD, PhD
Advertisement
Latest Updated Articles
Bringing Epigenetic Therapies From Bench to BedsidePublished: February 15th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5